Back to Search
Start Over
Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients.
- Source :
-
The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2008 Dec; Vol. 93 (12), pp. 4721-7. Date of Electronic Publication: 2008 Sep 23. - Publication Year :
- 2008
-
Abstract
- Context: Cabergoline fails to normalize hyperprolactinemia in a considerable proportion of prolactinomas, especially macroadenomas.<br />Objective: We examined the effect of individualized high-dose cabergoline treatment on hyperprolactinemia in prolactinomas.<br />Patients: The study included 122 women and 28 men (93 microadenomas and 57 macroadenomas). Forty-seven had undergone transsphenoidal surgery. According to the preceding medical treatment, the participants were separated into untreated (group U; n = 60), intolerant (group I; n = 64), and resistant (group R; n = 26) groups.<br />Interventions: We promptly increased cabergoline dose on the basis of individual prolactin levels. Length of treatment was 1 yr.<br />Results: Cabergoline normalized hyperprolactinemia in all patients except one. The proportion of prolactin normalization in both groups U and I was 83% at 3 months and 95% at 6 months. By contrast, that in group R was 35% at 3 months and 58% at 6 months. Mean cabergoline dose in milligrams per week at the time of prolactin normalization was 2.0 +/- 0.3 in group U, 0.9 +/- 0.1 in group I, and 5.2 +/- 0.6 in group R. Prolactin normalization rate at the 3 mg/wk dose was 84% overall but only 35% in group R. Serum progesterone or testosterone levels, diminished in 122 women or 16 men, respectively, were recovered in all except one resistant and four postmenopausal or panhypopituitary patients.<br />Conclusion: Individualized high-dose cabergoline treatment can normalize hyperprolactinemia and hypogonadism in nearly all prolactinomas irrespective of tumor size or preceding treatments. Hyperprolactinemia could be controlled in poor responders within 1 yr with doses higher than 3 mg/wk.
- Subjects :
- Adult
Aged
Antineoplastic Agents administration & dosage
Antineoplastic Agents adverse effects
Cabergoline
Combined Modality Therapy
Dose-Response Relationship, Drug
Drug Resistance
Ergolines administration & dosage
Ergolines adverse effects
Female
Humans
Male
Middle Aged
Neurosurgical Procedures
Pituitary Neoplasms radiotherapy
Pituitary Neoplasms surgery
Prolactin blood
Prolactinoma radiotherapy
Prolactinoma surgery
Prospective Studies
Young Adult
Antineoplastic Agents therapeutic use
Ergolines therapeutic use
Pituitary Neoplasms drug therapy
Prolactinoma drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 0021-972X
- Volume :
- 93
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- The Journal of clinical endocrinology and metabolism
- Publication Type :
- Academic Journal
- Accession number :
- 18812485
- Full Text :
- https://doi.org/10.1210/jc.2007-2758